The Latest Breaking News from Mersana rapeutics

Mersana Therapeutics's Return On Capital Employed Overview

According to Benzinga Pro data, during Q1, Mersana Therapeutics (NASDAQ:MRSN) posted sales of $2.04 million. Earnings were up 3.52%, but Mersana Therapeutics still reported an overall loss of $47.26 million.

Benzinga · Jun 3, 2022

Executives Buy Around $17M Of 5 Penny Stocks

The Nasdaq Composite index tumbled by more than 550 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their…

Benzinga · May 19, 2022

Recap: Mersana Therapeutics Q1 Earnings

  Mersana Therapeutics (NASDAQ:MRSN) reported its Q1 earnings results on Monday, May 9, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Benzinga · May 9, 2022